6550 Polaris Pharmaceuticals-KY Suspension of Phase III Clinical Trial for LMS
Polaris Pharmaceuticals-KY announced the suspension of its Phase III clinical trial for ADI-PEG 20 in treating leiomyosarcoma (LMS), following recommendations from the Data Safety Monitoring Board (DSMB). The company plans to optimize the trial design.
📋 Article Processing Timeline
- 📰 Published: May 26, 2026 at 06:31
- 🔍 Collected: May 26, 2026 at 06:31 (0 min after Published)
- 🤖 AI Analyzed: May 31, 2026 at 20:13 (133h 41m after Collected)
On May 25, 2025, Polaris Pharmaceuticals-KY announced the decision to suspend its Phase III multi-center clinical trial of ADI-PEG 20 in combination with Gemcitabine and Docetaxel for the treatment of leiomyosarcoma (LMS). This decision follows a review by the Data Safety Monitoring Board (DSMB). The company will now focus on optimizing the patient population and trial design. There is no material impact on the company's financial or operational status at this time.
FAQ
Why was the clinical trial suspended?
Based on DSMB recommendations to optimize the trial design.